Company Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection.
The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.
The company was incorporated in 2012 and is based in Alpharetta, Georgia.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Gregory Duncan |
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia 30009 United States | |
| Phone | 866 620 8655 |
| Website | dwtx.com |
Stock Details
| Ticker Symbol | DWTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818844 |
| ISIN Number | US92829J2033 |
| Employer ID | 85-4314201 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory Duncan | Chairman and Chief Executive Officer |
| Dr. William L. Pridgen M.D. | Founder and Member of Scientific Advisory Board |
| Angela Walsh | Chief Financial Officer, Secretary and Treasurer |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Ralph D. Grosswald M.P.H. | Senior Vice President of Operations |
| Carol Duffy Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2025 | 8-K | Current Report |
| Jun 26, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 24, 2025 | 8-K | Current Report |
| Jun 2, 2025 | EFFECT | Notice of Effectiveness |
| May 28, 2025 | UPLOAD | Filing |
| May 23, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 9, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |